BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35354247)

  • 1. Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma.
    Usmani SZ; Nahi H; Legiec W; Grosicki S; Vorobyev V; Spicka I; Hungria V; Korenkova S; Bahlis NJ; Flogegard M; Bladé J; Moreau P; Kaiser M; Iida S; Laubach J; Magen H; Cavo M; Hulin C; White D; De Stefano V; Lantz K; O'Rourke L; Heuck C; Delioukina M; Qin X; Nnane I; Qi M; Mateos MV
    Haematologica; 2022 Oct; 107(10):2408-2417. PubMed ID: 35354247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study.
    Iida S; Ishikawa T; Min CK; Kim K; Yeh SP; Usmani SZ; Mateos MV; Nahi H; Heuck C; Qin X; Parasrampuria DA; Gries KS; Qi M; Bahlis N; Ito S
    Ann Hematol; 2021 Apr; 100(4):1065-1077. PubMed ID: 33599794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.
    Mateos MV; Nahi H; Legiec W; Grosicki S; Vorobyev V; Spicka I; Hungria V; Korenkova S; Bahlis N; Flogegard M; Bladé J; Moreau P; Kaiser M; Iida S; Laubach J; Magen H; Cavo M; Hulin C; White D; De Stefano V; Clemens PL; Masterson T; Lantz K; O'Rourke L; Heuck C; Qin X; Parasrampuria DA; Yuan Z; Xu S; Qi M; Usmani SZ
    Lancet Haematol; 2020 May; 7(5):e370-e380. PubMed ID: 32213342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results.
    Usmani SZ; Mateos MV; Hungria V; Iida S; Bahlis NJ; Nahi H; Magen H; Cavo M; Hulin C; White D; De Stefano V; Fastenau J; Slavcev M; Heuck C; Qin X; Pei H; Masterson T; Lantz K; Gries KS
    J Cancer Res Clin Oncol; 2021 Feb; 147(2):619-631. PubMed ID: 32852632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO).
    San-Miguel J; Usmani SZ; Mateos MV; van de Donk NWCJ; Kaufman JL; Moreau P; Oriol A; Plesner T; Benboubker L; Liu K; Hellemans P; Masterson T; Clemens PL; Luo M; Farnsworth A; Nahi H; Chari A
    Haematologica; 2021 Jun; 106(6):1725-1732. PubMed ID: 32354874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma.
    Mateos MV; Rigaudeau S; Basu S; Spicka I; Schots R; Wrobel T; Cook G; Beksac M; Gries KS; Kudva A; Tromp B; Van Rampelbergh R; Pei H; Wroblewski S; Carson R; Delioukina M; White D
    J Oncol Pharm Pract; 2023 Jul; 29(5):1172-1177. PubMed ID: 36067063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study.
    Chari A; Rodriguez-Otero P; McCarthy H; Suzuki K; Hungria V; Sureda Balari A; Perrot A; Hulin C; Magen H; Iida S; Maisnar V; Karlin L; Pour L; Parasrampuria DA; Masterson T; Kosh M; Yang S; Delioukina M; Qi M; Carson R; Touzeau C
    Br J Haematol; 2021 Mar; 192(5):869-878. PubMed ID: 33216361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
    Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
    Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous delivery of daratumumab in Japanese patients with relapsed/refractory multiple myeloma.
    Shibayama H; Matsumoto M; Kosugi H; Shibayama K; Yamazaki H; Iida S
    Int J Hematol; 2021 Jan; 113(1):112-121. PubMed ID: 32915384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Pharmacokinetics and Pharmacodynamics of Daratumumab.
    Kim K; Phelps MA
    Clin Pharmacokinet; 2023 Jun; 62(6):789-806. PubMed ID: 37129750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma.
    Zhou X; Steinhardt MJ; Grathwohl D; Meckel K; Nickel K; Leicht HB; Krummenast F; Einsele H; Rasche L; Kortüm KM
    Cancer Med; 2020 Aug; 9(16):5819-5826. PubMed ID: 32608149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.
    Usmani SZ; Nahi H; Mateos MV; van de Donk NWCJ; Chari A; Kaufman JL; Moreau P; Oriol A; Plesner T; Benboubker L; Hellemans P; Masterson T; Clemens PL; Luo M; Liu K; San-Miguel J
    Blood; 2019 Aug; 134(8):668-677. PubMed ID: 31270103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Administration Characteristics of Subcutaneous and Intravenous Administration of Daratumumab in Patients With Multiple Myeloma at Mayo Clinic Infusion Centers.
    Soefje SA; Carpenter C; Carlson K; Awasthi S; Lin TS; Kaila S; Tarjan D; Kayal N; Kirkup C; Wagner TE; Gray KS; Kumar S
    JCO Oncol Pract; 2023 Apr; 19(4):e542-e549. PubMed ID: 36758192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience of Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multicenter Study from Türkiye.
    Tekinalp A; Gedük A; Akdeniz A; Terzi Demirsoy E; Gürsoy V; Aslaner Ak M; Bağcı M; Seçilmiş S; Keklik Karadağ F; Oruç Uysal A; Doğan A; Demircioğlu S; Erol HA; Aslan C; Özkalemkaş F; Ertop Ş; Dağlı M; Dal MS; Saydam G; Merter M; Ural C; Çeneli Ö
    Turk J Haematol; 2023 Dec; 40(4):242-250. PubMed ID: 37961952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of a Time and Motion Survey Regarding Subcutaneous versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma.
    Slavcev M; Spinelli A; Absalon E; Masterson T; Heuck C; Lam A; De Cock E
    Clinicoecon Outcomes Res; 2021; 13():465-473. PubMed ID: 34135605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients.
    Luo MM; Usmani SZ; Mateos MV; Nahi H; Chari A; San-Miguel J; Touzeau C; Suzuki K; Kaiser M; Carson R; Heuck C; Qi M; Zhou H; Sun YN; Parasrampuria DA
    J Clin Pharmacol; 2021 May; 61(5):614-627. PubMed ID: 33145788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daratumumab therapy for relapsed or refractory multiple myeloma: a single-center retrospective study.
    Sunami K; Murakami H; Tagashira H; Ueda H; Moriyama T; Ishikawa T; Yoshioka T; Makita M
    Int J Clin Oncol; 2020 Dec; 25(12):2151-2157. PubMed ID: 32715356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
    Dimopoulos MA; Terpos E; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Baldini L; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Ahmadi T; Ukropec J; Kampfenkel T; Schecter JM; Qiu Y; Amin H; Vermeulen J; Carson R; Sonneveld P;
    Lancet Oncol; 2021 Jun; 22(6):801-812. PubMed ID: 34087126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma.
    Chim CS; Kumar S; Wong VKC; Ngai C; Kwong YL
    Hematology; 2021 Dec; 26(1):652-655. PubMed ID: 34474661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of pomalidomide-based and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma: A real-world cohort study in China.
    Han X; Jiang X; He J; Zheng G; Xiong Y; Wen Y; Yang Y; He D; Chen Q; Zhao Y; Li Y; Wu W; Cai Z
    Cancer Med; 2024 May; 13(9):e7232. PubMed ID: 38698679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.